Skip to main content
Figure 2 | BMC Endocrine Disorders

Figure 2

From: A randomized controlled trial of the efficacy and safety of twice-daily saxagliptin plus metformin combination therapy in patients with type 2 diabetes and inadequate glycemic control on metformin monotherapy

Figure 2

Mean change from baseline HbA1c and fasting plasma glucose (FPG). A. Mean (SE) change from baseline HbA1c during the double-blind treatment period. BID = twice daily; HbA1c = glycated hemoglobin; SAXA = saxagliptin. Mean (SE) baseline values were 7.92% (0.11) in the saxagliptin group and 7.97% (0.09) in the placebo group. B. Mean (SE) change from baseline fasting plasma glucose (FPG) during the double-blind treatment period. BID = twice daily; FPG = fasting plasma glucose; SAXA = saxagliptin. Mean (SE) baseline values were 164.22 mg/dL (5.51) in the saxagliptin group and 161.25 mg/dL (4.62) in the placebo group.

Back to article page

BMC Endocrine Disorders

ISSN: 1472-6823

Contact us